Search - tctmd.com

Displaying 1 - 20 of 76

Sort: Relevancy | Date

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

September 05, 2025

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

News Conference News EuroPCR 2025

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

Michael O'Riordan

May 29, 2025

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

News Conference News EuroPCR 2025

Stroke Risk Higher With TAVI vs Surgery at 5 Years: UK TAVI

Michael O'Riordan

May 23, 2025

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

News Conference News TCT 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Michael O'Riordan

November 06, 2024

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

News Conference News ESC 2024

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

September 02, 2024

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

Registry Results See Less PVL, Pacemakers With Acurate neo2

News Conference News PCR London Valves 2022

Registry Results See Less PVL, Pacemakers With Acurate neo2

November 29, 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

News Conference News TCT 2022

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Michael O'Riordan

September 18, 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery

News Conference News ACC 2022

POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery

April 02, 2022

Longer-Term LRT Results ‘Encouraging’ for TAVI in Low-risk Patients

News Conference News

Longer-Term LRT Results ‘Encouraging’ for TAVI in Low-risk Patients

March 01, 2022

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

News Conference News ESC 2021

PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer

Michael O'Riordan

August 30, 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

News Conference News ESC 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

Michael O'Riordan

August 30, 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

Rogers.1-CRT2021.jpg

News Conference News CRT 2021

LRT Trial Data Bolster Support for TAVI in Bicuspid Valves

March 11, 2021

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

News Conference News TVT 2020

Reduced Leaflet Motion After TAVR: No Link to Impaired Hemodynamics, Events

Michael O'Riordan

June 23, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.